How Much Did EpiBiome Raise?
Funding & Key Investors

EpiBiome, a pioneer in the development of high-throughput automated phage discovery platforms, has successfully secured significant capital to advance its mission of addressing high unmet medical needs. The company's total capitalization has reached $12.6M, bolstered by a recent funding round totaling $1M. This major strategic investment underscores the growing market confidence in the firm's ability to leverage next-generation sequencing and machine learning to combat complex pathogens.

The trajectory of EpiBiome reflects a disciplined approach to growth, moving from its foundational roots in the Illumina Accelerator to securing substantial backing from institutional investors. This latest infusion of capital positions the company to scale its proprietary technology, which integrates bioinformatics and directed evolution to create highly targeted phage cocktails.